Research Topics
| Hua Xin LiaoSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteinsHua Xin Liao
Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
J Virol 78:5270-8. 2004....- Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine designMattia Bonsignori
Duke Human Vaccine Institute, Durham, North Carolina, USA
J Virol 86:4688-92. 2012..These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities... - Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41S Moses Dennison
Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
PLoS ONE 6:e27824. 2011..Nonetheless, the Env-liposome prime-boost immunization strategy induced antibodies that recognized a gp41 fusion intermediate protein and was successful in focusing the antibody response to the desired epitope... - Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2Hua Xin Liao
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
Immunity 38:176-86. 2013..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options... - HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineagesM Anthony Moody
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA
J Virol 86:7496-507. 2012..Improved vaccination strategies will be needed to drive persistent stimulation of antibody clonal lineages to induce affinity maturation that results in highly mutated HIV-1 Env-reactive antibodies... - Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletionS Munir Alam
Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
J Virol 87:1554-68. 2013..These results demonstrate that deletion of N-terminal residues in the RV144 A244 gp120 immunogen improves both envelope antigenicity and immunogenicity... - A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesHua Xin Liao
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
Virology 353:268-82. 2006..Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes... - Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infectionS Munir Alam
Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
J Virol 82:115-25. 2008.... 
Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolatesBarton F Haynes
Department of Medicine and Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
Virology 345:44-55. 2006....- Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sortingLynn Morris
Duke Human Vaccine Institute and Departments of Medicine, Surgery and Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
PLoS ONE 6:e23532. 2011..These data indicate that there are multiple immunogenic targets in the C-terminus of the MPER of HIV-1 gp41 envelope and suggests that gp41 neutralizing epitopes may interact with a restricted set of naive B cells during HIV-1 infection... - Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokinesM Anthony Moody
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
J Exp Med 207:763-76. 2010..The release of these beta-chemokines explains both the specificity for R5 HIV-1 and the activity of these mAbs in PBMC cultures containing both primary lymphocytes and monocytes... - Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoproteinFeng Gao
Department of Medicine, Duke University Medical Center, 112 Research Park III, Research Dr, Box 3347, Durham, NC 27710, USA
J Virol 79:1154-63. 2005..Thus, the computer-generated "consensus" env genes are capable of expressing envelope glycoproteins that retain the structural, functional, and immunogenic properties of wild-type HIV-1 envelopes... - Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesGuang Yang
Department of Immunology, Duke University, Durham, NC 27705, USA
J Exp Med 210:241-56. 2013..Identification of structural motifs shared by vertebrates and HIV-1 provides direct evidence that immunological tolerance can impair humoral responses to HIV-1... - Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformationS Munir Alam
Human Vaccine Institute, Duke University Medical Center, 2 Genome Court, P O Box 103020, Durham, NC 27710, USA
J Virol 85:11725-31. 2011..Thus, these data demonstrate a genetically determined trait that may affect host responses to HIV-1 envelope epitopes recognized by broadly neutralizing antibodies and has implications for unmutated ancestor-based immunogen design... - Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodiesBarton F Haynes
Duke University School of Medicine, Durham, NC 27710, USA
Science 308:1906-8. 2005..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines... - Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigensS Moses Dennison
Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
J Virol 85:1340-7. 2011..These results demonstrate that lipid-reactive gp41 cluster II antibodies are nonneutralizing due to their inability to bind to the relevant neutralizing epitopes on gp41... - Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedHua Xin Liao
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
J Exp Med 208:2237-49. 2011..These data suggest that the majority of gp41-binding antibodies produced after acute HIV-1 infection are cross-reactive responses generated by stimulating memory B cells that have previously been activated by non-HIV-1 antigens... - Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensorJae Sung Yu
Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, United States
J Virol Methods 137:219-28. 2006..Thus, polyclonal and monoclonal antibodies can be used in combination to identify and differentiate both human and non-human primate EBOV GPs... - Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sitesJae Sung Yu
Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Vaccine Immunol 14:886-93. 2007..However, rBCG could prime for a protein boost by HIV-1 envelope protein. Thus, rBCG can serve as a vector for induction of anti-HIV-1 consensus Env cellular responses at mucosal sites... - B cell responses to HIV-1 infection and vaccination: pathways to preventing infectionBarton F Haynes
Duke Human Vaccine Institute and the Duke Center for AIDS Research, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
Trends Mol Med 17:108-16. 2011.... - Role of HIV membrane in neutralization by two broadly neutralizing antibodiesS Munir Alam
Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 106:20234-9. 2009..These results bear directly on strategies for rational design of HIV-1 envelope immunogens... 
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine designMattia Bonsignori
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
Trends Microbiol 20:532-9. 2012..Strategies are being developed for the analysis of infection and vaccine candidate-induced antibodies, their gene usage, and their maturation pathways such that this information can be used to attempt to guide rational vaccine design...- Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteinsFeng Gao
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
Virology 394:91-8. 2009..Nonetheless, such mAbs represent valuable reagents to study the biochemistry and structural biology of Env protein oligomers... - Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyMattia Bonsignori
Duke University Medical Center, Durham, North Carolina, USA
J Virol 86:11521-32. 2012..The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbs... - Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsMattia Bonsignori
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Virol 85:9998-10009. 2011..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies... - Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteinsJae Sung Yu
Departments of Medicine, Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
J Virol Methods 168:248-50. 2010..Thus, while MAbs 15H10 and 6D11 are indeed EBOV GP specific, MAb 17A3 is an alpha-2-macroglobulin MAb... - Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes
Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
N Engl J Med 366:1275-86. 2012..In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk... - Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodiesBen Jiang Ma
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
PLoS Pathog 7:e1002200. 2011.... - Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external regionNathan I Nicely
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
Nat Struct Mol Biol 17:1492-4. 2010..We show that unlike 2F5, 13H11 binds to a well-defined helical MPER structure that is consistent with the structure of gp41 in a post-fusion six-helix bundle conformation... - Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon productionAnthony R Geonnotti
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
AIDS Res Hum Retroviruses 26:279-91. 2010..The results also highlight the need to use endotoxin-free specimens to avoid artifacts when assessing HIV-1-specific neutralizing antibodies in PBMC-based assays... - Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic toleranceLaurent Verkoczy
Duke Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Proc Natl Acad Sci U S A 107:181-6. 2010..These features are consistent with elimination of 2F5 HC autoreactivity by additional negative selection mechanism(s) in the periphery... - epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individualsHaili Tang
Department of Surgery, Box 2926, Duke University Medical Center, Durham, NC 27710, USA
J Virol 85:9286-99. 2011..We conclude that a region just below the base of the V3 loop, near the coreceptor binding domain of gp120, can be a target for autologous neutralization... - Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cellsKwan Ki Hwang
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
Blood 119:e35-44. 2012..Thus, we have established enhanced methods of B-CLL culture that will enable broader interrogation of B-CLL cells at the genetic and protein levels... - Murine CD7 shares antigenic cross-reactivity with HSP-60Brandon A Howard
Departments of Medicine, Duke University Medical Center, Duke Human Vaccine Institute, Durham, North Carolina, USA
Hybridoma (Larchmt) 27:81-9. 2008..These data demonstrated molecular mimicry of mCD7 with HSP-60, and leave open the question of surface expression of mCD7... - A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitroWoohyun Yoon
Center for Human Genome Variation, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
AIDS 24:155-7. 2010.... - Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regionsS Moses Dennison
Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
J Virol 83:10211-23. 2009..These data have important implications for the design and use of peptide-liposome conjugates as immunogens for the induction of MPER-neutralizing antibodies... - Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaGeorgia D Tomaras
Duke Human Vaccine Institute, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Virol 82:12449-63. 2008..These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection... - Centralized immunogens as a vaccine strategy to overcome HIV-1 diversityFeng Gao
The Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
Expert Rev Vaccines 3:S161-8. 2004..It is biologically functional and preserves antigenicity similar to contemporary Env proteins. Most importantly, the group M consensus Env immunogen can elicit both T- and B-cell responses to wild-type HIV-1 isolates... - Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individualElin S Gray
Duke Human Vaccine Institute and Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
J Virol 85:7719-29. 2011..Our data validate the use of differential sorting to isolate a MAb targeting a specific epitope in the envelope glycoprotein and provided insights into the mechanisms of autologous neutralization escape... - High throughput functional analysis of HIV-1 env genes without cloningJennifer L Kirchherr
Duke Human Vaccine Institute and Center for HIV AIDS Vaccine Immunology, Department of Medicine, Duke University Medical Center, 112 RPIII, Research Drive, Box 3347, Durham, NC 27710, USA
J Virol Methods 143:104-11. 2007..The new pPCR method eliminates cloning, transformation, and plasmid DNA preparation steps in the generation of HIV-1 pseudovirions. This allows for quick analysis of multiple env genes from HIV-1 infected individuals... - Is developing an HIV-1 vaccine possible?Barton F Haynes
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
Curr Opin HIV AIDS 5:362-7. 2010..This review discusses select recent data that suggest that indeed it is possible to make a clinically useful preventive vaccine for HIV-1 and outlines some of the remaining obstacles that stand in the way of success... - Centralized HIV-1 envelope immunogens and neutralizing antibodiesFeng Gao
Duke Human Vaccine Institute, Duke University Medical Center, Durham NC 27710, USA
Curr HIV Res 5:572-7. 2007.... - Comparison of multiple vaccine vectors in a single heterologous prime-boost trialBrice Barefoot
Duke Human Vaccine Institute, Duke University School of Medicine, DU Medical Center, 102 Research Drive, Durham, NC 27710, USA
Vaccine 26:6108-18. 2008..Comparative data such as those presented here are critical to efforts to generate protective vaccines for emerging infectious diseases as well as for biothreat agents... - Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSFHua Xin Liao
Department of Medicine, Duke Human Vaccine Institute, Duke University Medical Center, Box 3258, Durham, NC 27710, USA
Vaccine 20:2396-403. 2002.... - Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infectionMarc C Levesque
Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America
PLoS Med 6:e1000107. 2009..While the effect of HIV-1 on depletion of gut CD4(+) T cells in acute HIV-1 infection is well described, we studied blood and tissue B cells soon after infection to determine the effect of early HIV-1 on these cells... - An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120S Munir Alam
Department of Medicine, Duke Center for AIDS Research, Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina 27707, USA
AIDS Res Hum Retroviruses 20:836-45. 2004..This may prove to be an important consideration when designing an HIV vaccine that utilizes constrained HIV Env proteins... - Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challengeNatalie J Thornburg
Carolina Vaccine Institute, 9th Floor Burnett Womack, West Drive, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7292, USA
Virology 362:441-52. 2007..These results demonstrate that VRP may provide an effective alternative to vaccinia virus vaccines against poxvirus infection... - Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boostingJames W Peacock
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Virol 78:13163-72. 2004..Understanding the cellular and molecular basis of gender-determined immune responses will be important for optimizing induction of anti-HIV-1 mucosal immune responses in both males and females... - Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodiesMikyung Kim
Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
AIDS Res Hum Retroviruses 21:58-67. 2005..This ADAgp140 immunogen may be considered a starting point from which to engineer additional improvements for cross-reactive neutralizing antibody induction... - Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogenEric A Weaver
Duke Human Vaccine Institute, Duke University Medical Center, 112 RPIII, Research Drive, Box 3347, DUMC, Durham, NC 27710, USA
J Virol 80:6745-56. 2006.... - Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunizationCurtis P Bradney
Department of Medicine, Human Vaccine Institute, Center for AIDS Research, Duke University Medical Center, Durham, North Carolina 27710, USA
J Virol 76:517-24. 2002..These results indicate that the proinflammatory cytokines IL-1alpha, IL-12, and IL-18 can replace CT as a mucosal adjuvant for antibody induction and are important candidates for use as mucosal adjuvants with HIV and other vaccines... - Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatisJae-Sung Yu
Human Vaccine Institute and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Vaccine Immunol 13:1204-11. 2006..However, immunization with recombinant M. smegmatis expressing HIV-1 Env was able to prime for an HIV-1 Env protein boost for the induction of anti-HIV-1 antibody responses... - Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibilityEden P Go
Department of Chemistry, University of Kansas, Lawrence, Kansas 66045, USA
J Proteome Res 7:1660-74. 2008.... - Expression of the CD7 ligand K-12 in human thymic epithelial cells: regulation by IFN-gammaGordon K Lam
Department of Medicine, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
J Clin Immunol 25:41-9. 2005..These data suggest a role for thymic microenvironment-produced K12 in regulation of thymocyte signaling and cytokine release, particularly in the setting of thymus pathology where IFN-gamma is upregulated such as myasthenia gravis...